Fagron to present its upgraded growth strategy and mid-term financial targets at its Capital Markets Day 2025 ...

Revenue maintained its strong growth momentum, increasing 14.1% on reported basis to €238.7 million (15.2% at CER), with all regions and segments contributing Organic growth at CER of 12.6% reflects ...

CEO and Founder of Oxford Healthspan Leslie Kenny turned her own life-altering autoimmune diagnosis into a mission to ...

The Symposium will feature scientific leaders who are creating cutting edge technologies and approaches for building the ...

Private Placement: In November 2024, the Company completed a second tranche of a non-brokered private placement, issuing 231,818 units at C$0.55 per unit, raising aggregate gross proceeds of C$127 ...

Amezalpat (TPST-1120) is Phase 3-ready: completed FDA and EMA interactions for first-line pivotal study in hepatocellular carcinoma (HCC); global investigator support in place Awarded both Orphan Drug ...

Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that on April 3, 2025, the Compensation Committee granted inducement awards consisting of non-qualified stock options to purchase 211,250 shares ...

This press release does not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any jurisdiction in which such offer ...

Mr. Dorgan added, “It has been a privilege to serve on the Codexis Board alongside a group of bright and passionate directors for almost 15 years. I am incredibly proud of our progress toward ...

Ongoing streamlined efficiencies and cost cutting measures taken to refine operations and development pathway forward; Company ended the quarter with US$16.4 million in cash Revenues of US$9.6M vs ...

AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound care company delivering a portfolio of transformative solutions, today announced 16 abstracts to be presented at the ...

We’re thrilled to welcome Richard to our board,” said Richard A. Miller, M.D., chairman, president and chief executive officer of Corvus. “Richard has a proven track record in the biotechnology sector ...